Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease

J. Málly, Attila B. Kovacs, T. W. Stone

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Twenty de novo patients with Parkinson's disease (Hoehn-Yahr stages I, II, III) were studied in a double blind trial after introducing (-)-deprenyl monotherapy. The parkinsonian symptoms were assessed by a novel graded clinical rating scale, by UPDRS and by the North Western self-rating scale. A significant change was observed in motor behaviour and daily activity (UPDRS) after 3 weeks of treatment with (-)-deprenyl at 10 mg/day. The total scores using UPDRS and the North Western ratings were changed significantly after 4 weeks. The greatest changes observed were in walking and in hypokinesia. Rigidity was not modified by (-)-deprenyl.

Original languageEnglish
Pages (from-to)143-145
Number of pages3
JournalJournal of the Neurological Sciences
Volume134
Issue number1-2
DOIs
Publication statusPublished - 1995

Fingerprint

Selegiline
Parkinson Disease
Hypokinesia
Walking
Therapeutics

Keywords

  • (-)-Deprenyl
  • MAO-B
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Ageing
  • Surgery
  • Developmental Neuroscience
  • Neuroscience(all)

Cite this

Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. / Málly, J.; Kovacs, Attila B.; Stone, T. W.

In: Journal of the Neurological Sciences, Vol. 134, No. 1-2, 1995, p. 143-145.

Research output: Contribution to journalArticle

@article{a4fbe632dc7e467d85c768b21753b55e,
title = "Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease",
abstract = "Twenty de novo patients with Parkinson's disease (Hoehn-Yahr stages I, II, III) were studied in a double blind trial after introducing (-)-deprenyl monotherapy. The parkinsonian symptoms were assessed by a novel graded clinical rating scale, by UPDRS and by the North Western self-rating scale. A significant change was observed in motor behaviour and daily activity (UPDRS) after 3 weeks of treatment with (-)-deprenyl at 10 mg/day. The total scores using UPDRS and the North Western ratings were changed significantly after 4 weeks. The greatest changes observed were in walking and in hypokinesia. Rigidity was not modified by (-)-deprenyl.",
keywords = "(-)-Deprenyl, MAO-B, Parkinson's disease",
author = "J. M{\'a}lly and Kovacs, {Attila B.} and Stone, {T. W.}",
year = "1995",
doi = "10.1016/0022-510X(95)00240-1",
language = "English",
volume = "134",
pages = "143--145",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease

AU - Málly, J.

AU - Kovacs, Attila B.

AU - Stone, T. W.

PY - 1995

Y1 - 1995

N2 - Twenty de novo patients with Parkinson's disease (Hoehn-Yahr stages I, II, III) were studied in a double blind trial after introducing (-)-deprenyl monotherapy. The parkinsonian symptoms were assessed by a novel graded clinical rating scale, by UPDRS and by the North Western self-rating scale. A significant change was observed in motor behaviour and daily activity (UPDRS) after 3 weeks of treatment with (-)-deprenyl at 10 mg/day. The total scores using UPDRS and the North Western ratings were changed significantly after 4 weeks. The greatest changes observed were in walking and in hypokinesia. Rigidity was not modified by (-)-deprenyl.

AB - Twenty de novo patients with Parkinson's disease (Hoehn-Yahr stages I, II, III) were studied in a double blind trial after introducing (-)-deprenyl monotherapy. The parkinsonian symptoms were assessed by a novel graded clinical rating scale, by UPDRS and by the North Western self-rating scale. A significant change was observed in motor behaviour and daily activity (UPDRS) after 3 weeks of treatment with (-)-deprenyl at 10 mg/day. The total scores using UPDRS and the North Western ratings were changed significantly after 4 weeks. The greatest changes observed were in walking and in hypokinesia. Rigidity was not modified by (-)-deprenyl.

KW - (-)-Deprenyl

KW - MAO-B

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0028824983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028824983&partnerID=8YFLogxK

U2 - 10.1016/0022-510X(95)00240-1

DO - 10.1016/0022-510X(95)00240-1

M3 - Article

VL - 134

SP - 143

EP - 145

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -